DPP4 and Alzheimer disease: In a study conducted on the data of 11,612 patients with type 2 diabetes in Taiwan, it was concluded that the use of DPP-4 inhibitors with a class effect reduced the risk of all-cause dementia (hazard ratio (HR): 0.798; 95% confidence interval (CI): 0.681-0.883; p<0.001), particularly vascular dementia (HR: 0.575; 95% CI: 0.404-0.681; p<0.001), but not in AD (HR: 0.891; 95% CI: 0.712-1.265; p=0.297) when compared to patients not using DPP-4 inhibitors (p<0.001) [20].